Table 3 Initial and Follow Up Assessments for Skin Predominant Juvenile Dermatomyositis Patients

Initial

 A. Basic Assessment

  a. Cutaneous Disease Activity Visual Analogue Scale from the Myositis Disease Activity Assessment Tool (MDAAT)

  b. Physician global assessment of disease activity (10-cm VAS)

  c. Patient/Parent global assessment of disease activity (10-cm VAS)

  d. Physician Extramuscular disease activity (10-cm VAS)

  e. CHAQ

  f. Strength Testing: CMAS or Manual muscle testing

  g. Documentation of muscle involvement if performed (e.g. MRI, EMG, biopsy results)

  h. Muscle enzymes (preferably several among serum levels of ALT, AST, LDH, CK, aldolase)

  i. Baseline laboratory testing (include complete blood cell count, immunoglobulins)

  j. Nailfold capillaroscopy (using hand-held magnifier, ophthalmoscope, or microscope)

 B. Expanded assessment (Basic plus items below)

  a. ANA and other autoantibodies (myositis-specific and myositis-associated)

  b. Full PRINTO core set activity measures, including Disease Activity Score and Health-Related Quality of Life* [32]

Follow-up

 A. Basic Assessment

  a. Cutaneous Disease Activity Visual Analogue Scale from the Myositis Disease Activity Assessment Tool (MDAAT)

  b. Physician global assessment of disease activity (10-cm VAS)

  c. Patient/Parent global assessment of disease activity (10-cm VAS)

  d. Physician Extramuscular disease activity (10-cm VAS)

  e. CHAQ

  f. Strength Testing: CMAS or Manual muscle testing

  g. Muscle enzymes (preferably several of ALT, AST, LDH, CK, aldolase)

  h. Nailfold capillaroscopy (using hand-held magnifier, ophthalmoscope, or microscope)

 B. Expanded Assessment (Basic plus items below)

  a. Full PRINTO core set activity measures [32]